ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Levels Of Heparin Induced Anti-PF4 Antibodies and Endogenous Glycosaminoglycans and Their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients.

B. Kantarcioglu1, A. Darki2, F. Siddiqui2, D. Hoppensteadt2, J. Lewis3, R. Krämer4, J. Fareed2

1Loyola University Chicago, Oak Park, Illinois, United States, 2Loyola University Chicago, Maywood, Illinois, United States, 3Loyola University Chicago, Northfield, Illinois, United States, 4Heidelberg University, Heidelberg, Baden-Wurttemberg, Germany

Abstract Number: VPB0468

Meeting: ISTH 2022 Congress

Theme: Venous Thromboembolism » VTE Treatment

Background: Increased levels of inflammatory cytokines have been shown in venous thrombosis. Endothelial damage and shedding of endothelial glycocalyx have also been shown in certain thrombotic disease states, conferring that they have important functions in circulatory homeostasis.

Aims: We sought to quantify the levels of anti-PF4 antibody isotypes together with endogenous glycosaminoglycans (GAGs) in a patient cohort, comprised of PE, to determine their impact on pathophysiology of VTE and HIT and observe whether there is a relationship in between and inflammatory marker subtypes.

Methods: Whole blood samples were drawn from patients within 24 hours of confirmed diagnosis of acute PE under an Institutional Review Board approved protocol. The samples were tested for anti-PF4 isotypes of IgA, IgG, and IgM ELISA assay, endogenous GAGs with heparin red assay and inflammatory biomarkers with biochip assay. Circulating levels of each biomarker were compared to control plasma. P < 0.05 was considered statistically significant.

Results: The levels of anti-PF4 Ig A, Ig G and endogenous GAGs were elevated in acute PE patients compared to normal controls (P < 0.05). The increase in anti-PF4 Ig M was not significant (p: 0.78). Anti PF4 Ig A were correlated with IL-2, IL-6 and TNFA. Anti PF4 Ig G were correlated with IL-6 and d-dimer. Anti PF4 Ig M were correlated with IL-2 and MCP-1. The levels of endogenous GAGs were correlated with TNF-α, IL-10, IL-8, IL-1β, IL-1α and VEGF. We observed significant correlations in between anti-PF4 antibody isotypes. The correlation between the levels of anti-PF4 isotypes and endogenous GAGs were insignificant.

Conclusion(s): Our findings supports that the development of thrombosis is likely due to releasing of PF4 antigen from platelets and shedding of endogenous GAGS from the endothelial cells causing activation of endothelial cells, platelets, and leukocytes, resulting in inflammatory cytokine release and triggering of the coagulation system.

Figure:

The Levels of Anti-PF4 Antibody Isotypes and Endogenous GAGs in acute PE patients and healthy controls.

Table:

Correlations Between Inflammatory Biomarkers, Anti-PF4 Isotypes and Endogenous GAGs.

To cite this abstract in AMA style:

Kantarcioglu B, Darki A, Siddiqui F, Hoppensteadt D, Lewis J, Krämer R, Fareed J. Levels Of Heparin Induced Anti-PF4 Antibodies and Endogenous Glycosaminoglycans and Their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients. [abstract]. https://abstracts.isth.org/abstract/levels-of-heparin-induced-anti-pf4-antibodies-and-endogenous-glycosaminoglycans-and-their-relationship-with-inflammatory-biomarkers-in-pulmonary-embolism-patients/. Accessed September 29, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/levels-of-heparin-induced-anti-pf4-antibodies-and-endogenous-glycosaminoglycans-and-their-relationship-with-inflammatory-biomarkers-in-pulmonary-embolism-patients/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley